20/20 BioLabs Posts $4.2M Cash, $0.4M Q1 Revenue; Evexia and ROKIT Deals
AIDX•20/20 BioLabs reported Q1 revenue of $0.4M, down from $0.6M year-over-year, and ended March with $4.2M cash after a $5M private placement. State firefighter programs, Evexia distribution and ROKIT CKD license support OneTest™ expansion and 2026 revenue growth ahead of Medicare MCED reimbursement in 2028.
1. First Quarter Financial Results
In Q1 2026, 20/20 BioLabs generated $0.4 million in revenue, down from $0.6 million in Q1 2025 due to order timing shifts, and reported deferred revenue of $0.5 million. The company’s cash and cash equivalents rose to $4.2 million as of March 31, 2026.
2. Strategic Partnerships and Product Launches
The company secured a Maryland firefighter cancer screening grant expected to drive Q2 revenue and received notice of a second comparable state program. It also struck a distribution agreement with Evexia Diagnostics, obtained a U.S. license from ROKIT Healthcare for chronic kidney disease testing, and launched the OneTest™ for Longevity.
3. Capital Raises and Reimbursement Outlook
On February 19, 2026, 20/20 BioLabs began trading on the Nasdaq Capital Market and completed a $5.0 million private placement under a facility that could provide up to $40 million. The Medicare Multi-Cancer Early Detection Screening Act now paves the way for MCED test reimbursement starting in 2028.
